Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BIO Stock Forecast 2025-2026
$315.00
Current Price
$8.50B
Market Cap
Buy 2
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to BIO Price Targets
+19.0%
To High Target of $375.00
+7.9%
To Median Target of $340.00
+3.2%
To Low Target of $325.00
BIO Price Momentum
-1.6%
1 Week Change
+0.5%
1 Month Change
-7.8%
1 Year Change
-4.1%
Year-to-Date Change
-15.7%
From 52W High of $373.69
+49.0%
From 52W Low of $211.43
📊 TOP ANALYST CALLS
Did BIO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bio-Rad is one of their latest high-conviction picks.
Latest BIO Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, BIO has a neutral consensus with a median price target of $340.00 (ranging from $325.00 to $375.00). The overall analyst rating is Buy (7.6/10). Currently trading at $315.00, the median forecast implies a 7.9% upside. This outlook is supported by 2 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 19.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BIO Analyst Ratings
2
Buy
3
Hold
0
Sell
BIO Price Target Range
Low
$325.00
Average
$340.00
High
$375.00
Current: $315.00
Latest BIO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BIO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 30, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $340.00 |
| Oct 30, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $375.00 |
| Aug 1, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $265.00 |
| Aug 1, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $409.00 |
| Jun 9, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $245.00 |
| May 2, 2025 | Citigroup | Patrick Donnelly | Buy | Maintains | $350.00 |
| May 2, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $392.00 |
| May 2, 2025 | UBS | Dan Leonard | Buy | Maintains | $310.00 |
| Apr 17, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $270.00 |
| Feb 12, 2025 | Wells Fargo | Brandon Couillard | Equal-Weight | Maintains | $345.00 |
| Jan 14, 2025 | RBC Capital | Conor McNamara | Outperform | Reiterates | $481.00 |
| Dec 9, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $481.00 |
| Oct 31, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $450.00 |
| Oct 31, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $469.00 |
| Oct 1, 2024 | Citigroup | Patrick Donnelly | Buy | Upgrade | $400.00 |
| Aug 27, 2024 | Wells Fargo | Brandon Couillard | Equal-Weight | Initiates | $340.00 |
| Aug 16, 2024 | RBC Capital | Conor McNamara | Outperform | Reiterates | $401.00 |
| Aug 2, 2024 | Citigroup | Patrick Donnelly | Neutral | Maintains | $350.00 |
| Aug 2, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $401.00 |
| Jun 3, 2024 | Jefferies | Hold | Assumes | $315.00 |
Bio-Rad Laboratories Inc. (BIO) Competitors
The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bio-Rad Laboratories Inc. (BIO) Financial Data
Bio-Rad Laboratories Inc. has a market capitalization of $8.50B with a P/E ratio of 29.8x. The company generates $2.56B in trailing twelve-month revenue with a -26.4% profit margin.
Revenue growth is +0.5% quarter-over-quarter, while maintaining an operating margin of +10.4% and return on equity of -9.5%.
Valuation Metrics
Market Cap
$8.50B
Enterprise Value
$8.55B
P/E Ratio
29.8x
PEG Ratio
-0.2x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+0.5%
Gross Margin
+52.6%
Operating Margin
+10.4%
Net Margin
-26.4%
EPS Growth
+0.5%
Financial Health
Cash/Price Ratio
+16.7%
Current Ratio
5.4x
Debt/Equity
20.7x
ROE
-9.5%
ROA
+1.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bio-Rad Laboratories Inc. (BIO) Business Model
About Bio-Rad Laboratories Inc.
What They Do
Manufactures life science research and clinical diagnostics products.
Business Model
Bio-Rad Laboratories Inc. generates revenue through the sale of a diverse range of life science research products and clinical diagnostics systems. Its offerings include reagents, instruments, and software that are essential for various laboratory techniques. The company serves both research laboratories and healthcare institutions, providing tools that support medical research and improve diagnostic accuracy.
Additional Information
Founded in 1952 and headquartered in Hercules, California, Bio-Rad plays a crucial role in healthcare and medical research. Its products aid in significant areas such as genetic analysis and disease diagnosis, impacting fields like diabetes and autoimmune testing. The company's comprehensive portfolio positions it as a leading entity in advancing global health and medical science.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,700
CEO
Mr. Norman D. Schwartz
Country
United States
IPO Year
1980
Website
www.bio-rad.comBio-Rad Laboratories Inc. (BIO) Latest News & Analysis
Latest News
Quick Summary
The diagnostics specialist reported third-quarter earnings that exceeded expectations, but low growth rates led to a negative market reaction.
Why It Matters
Low growth rates despite beating earnings can signal potential challenges ahead, leading to cautious investor sentiment and possible stock price volatility.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Bio-Rad Laboratories will hold its Q3 2025 earnings call on October 29, 2025, at 5:00 PM EDT, featuring key executives and analysts from major financial institutions.
Why It Matters
Bio-Rad's Q3 earnings call indicates upcoming financial results, which can influence stock performance and investor sentiment based on company performance and market expectations.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Bio-Rad Laboratories (NYSE: BIO, BIO.B) reported Q3 2025 financial results, highlighting challenges in the life science and clinical diagnostics markets. Further details on performance were not provided.
Why It Matters
Bio-Rad's Q3 financial results reveal its performance amid market challenges, impacting investor sentiment and expectations for future growth in life sciences and diagnostics sectors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bio-Rad Laboratories (BIO) reported quarterly earnings of $2.26 per share, below the Zacks Consensus Estimate of $2.30, but up from $2.01 per share a year prior.
Why It Matters
Bio-Rad's earnings miss signals potential weakness in performance, which may affect investor confidence and stock price, despite year-over-year growth.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
BIO's Q3 earnings missed estimates despite increased revenues, affected by margin pressure and weak research demand.
Why It Matters
BIO's Q3 earnings miss indicates operational challenges, impacting profitability despite revenue growth. This raises concerns about future performance and potential stock volatility.
Source: Zacks Investment Research
Market Sentiment:
Negative
7 Stocks Taking The Next Step To Be On Offense
1 month ago
Quick Summary
Bio-Rad Laboratories exceeded earnings expectations, positively impacting its stock. PVH continues to lead in share repurchases, acquiring a significant percentage of its shares. Rayonier also contributed positively.
Why It Matters
Bio-Rad's stronger-than-expected earnings can boost investor confidence, while PVH's aggressive share repurchase may enhance shareholder value, indicating positive market sentiment.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About BIO Stock
What is Bio-Rad Laboratories Inc.'s (BIO) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Bio-Rad Laboratories Inc. (BIO) has a median price target of $340.00. The highest price target is $375.00 and the lowest is $325.00.
Is BIO stock a good investment in 2026?
According to current analyst ratings, BIO has 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $315.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BIO stock?
Wall Street analysts predict BIO stock could reach $340.00 in the next 12 months. This represents a 7.9% increase from the current price of $315.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bio-Rad Laboratories Inc.'s business model?
Bio-Rad Laboratories Inc. generates revenue through the sale of a diverse range of life science research products and clinical diagnostics systems. Its offerings include reagents, instruments, and software that are essential for various laboratory techniques. The company serves both research laboratories and healthcare institutions, providing tools that support medical research and improve diagnostic accuracy.
What is the highest forecasted price for BIO Bio-Rad Laboratories Inc.?
The highest price target for BIO is $375.00 from Patrick Donnelly at Citigroup, which represents a 19.0% increase from the current price of $315.00.
What is the lowest forecasted price for BIO Bio-Rad Laboratories Inc.?
The lowest price target for BIO is $325.00 from at , which represents a 3.2% increase from the current price of $315.00.
What is the overall BIO consensus from analysts for Bio-Rad Laboratories Inc.?
The overall analyst consensus for BIO is neutral. Out of 7 Wall Street analysts, 2 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $340.00.
How accurate are BIO stock price projections?
Stock price projections, including those for Bio-Rad Laboratories Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 7:21 AM UTC